Sara Merler

📣 Great news! Our work has been published! A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024 - European Journal of Cancer ejcancer.com/article/S0959-…

#IUCS25 Abstract published on @OncJournal @saramerler @arenasabry @RebuzziSara @FabrizioDiCost @MicheleMaffezz @PasRescigno @JureMurgic @heyitsbasu @Arianna_Dri @gbanna74 @ManiamAkash @BenSmalley93 @NeolaGiuseppe @giulia_claire @mona_hssn @OncoAlert

🎤 Oral at #IUCS25: "Luminal/basal IHC subtyping may have prognostic value in mHSPC. #ProstateCancer" @saramerler @OncoAlert #cancer #urology

🎓 Happy to share that in May 2025 I finally completed my PhD path 🎉 @UniVr in "Inflammation, Immunity and Cancer". Thanks a lot for the valuable support to my tutor, Professor Michele Milella, and my co-supervisor, Professor Andrea Alimonti. So grateful 🙏

So honoured and grateful to share that I won the PIT grant award! Thrilled for the next steps!

10,000 patients worldwide! 🌍 We’ve reached a major milestone thanks to the incredible dedication of our global network. Thank you all! ❤️ #AronProject #10k #GlobalCollaboration

Back from the magic Genève for an amazing #ESMOIO congress with my super ex-colleagues 🔝

Great presentations at “Giornata della ricerca in Ticino” and amazing collaboration between IOSI and nuclear medicine at EOC. Excited to see more 🔜

@Cancer_Cell Another great paper from Alimonti’s lab!

Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells dlvr.it/T5Fbdt

I am so proud of being part of this amazing work from Alimonti’s lab! Great scientists, truly committed to prostate cancer research💪🏻

@ciccarese_c rocked the stage presenting preliminary data of TACITO trial investigating #FMT on #mRCC. Primary endpoint 1-y PFS met and no safety issues. Thanks to @gianluca1aniro leading the gastroenterology team & all coinvesigators for this significant achievement. @OncoAlert

Congratulations to @Silke_Gillessen and the team on the PEACE-3 study results! PEACE-3 trial shows a significant improvement in rPFS and OS with Enzalutamide + Ra223 in mCRPC with bone metastases. Time to SSE remained similar at 24 months (18%). #ESMO24 @oncoalert @myESMO @DrChoueiri @Silke_Gillessen #cancer #oncology @EORTC @APCCC_Lugano @yekeduz_emre @neerajaiims @CParkMD @PGrivasMDPhD @OncBrothers @Larvol @nataliagandur @sonpavde @MattGalsky @KatsuakiMaehara @amerseburger @drenriquegrande @urotoday @apolo_andrea @cdanicas @GGiannarini @dmukherji

Definitely the best event I’ve ever experienced. Thanks MCCR @EORTC ! Amazing time and incredible faculty @drcmassard @efrangou_stats @giannatempopatr PDG3 rules! #MCCR24

Fantastic day at #MCCR2024! Hard work and unforgettable moments @drcmassard @BenjaminBesseMD @ElenaGarralda @VicMorenoGarcia @EORTC @AACR @myESMO

Quel bambino ce l'ha fatta. That kid made it. Jannik #Sinner is the new world no. 1.

Part of my fantastic present, past and future #iosi young GU team #APCCC2024. All talented prostate cancer clinicians and researchers! Congrats @Silke_Gillessen - our medical director #iosi for a fantastic day 1! @fabioturco92 @oncoalert @APCCC_Lugano

Here are some take home messages from medical oncologist Dr. Sara Merler (IT) on her #EMUC23 lecture about how systematic treatment should be used for men with high-risk localised PCa in 2023. @myESMO @ESTRO_RT

Bellinzona and ⁦@AnkaraUni⁩ getting together at EMUC! ⁦@myESMO⁩ ⁦@Uroweb⁩ ⁦@ESTRO_RT⁩ ⁦@OncoAlert⁩ #emuc23 ⁦⁦@Silke_Gillessen⁩ ⁦@ZilliThomas⁩ ⁦@UrsulaVogl⁩ ⁦@yekeduz_emre⁩ ⁦@APCCC_Lugano⁩ and Sara Merler

🌟 Be part of a pivotal moment in advanced #prostatecancer managment at #APCCC24! Join global experts in consensus discussions that shape future treatments. 🗓️ Register now for an unmissable experience: apccc.org #Oncology #GU24 #oncoalert